Tveter K J, Otnes B, Hannestad R
Scand J Urol Nephrol. 1978;12(2):115-8. doi: 10.3109/00365597809179976.
Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was administered. Increasing skeletal metastases were observed in 6 patients, whereas significant reduction of metastases took place in 2 patients. Objective relief of stranguria was observed only in 3 patients. The amount of residual urine increased in 3 patients and was reduced in 5. In about one third of the patients, the prostate gland became smaller and softer. The acidic phosphatases decreased from pathological to normal values in 7 patients. There were no observed hepatic, renal or haemotological side-effects. However, serious cardio-vascular complications occurred in 6 patients, while arterial hypertension developed in 4. It is suggested that Cyproterone acetate cannot be recommended as the only kind of hormonal treatment of prostatic cancer.
16例前列腺癌患者每日接受200毫克醋酸环丙孕酮治疗。未给予其他类型的激素治疗。6例患者出现骨骼转移增加，而2例患者的转移灶显著减少。仅3例患者出现排尿困难的客观缓解。3例患者残余尿量增加，5例患者残余尿量减少。约三分之一的患者前列腺变小变软。7例患者酸性磷酸酶从病理值降至正常水平。未观察到肝脏、肾脏或血液学方面的副作用。然而，6例患者出现严重心血管并发症，4例患者出现动脉高血压。建议不推荐将醋酸环丙孕酮作为前列腺癌唯一的激素治疗方法。
